Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022.
MMWR Morb Mortal Wkly Rep
; 71(17): 606-608, 2022 Apr 29.
Article
in English
| MEDLINE | ID: covidwho-1818832
ABSTRACT
In December 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, became predominant in the United States. Subsequently, national COVID-19 case rates peaked at their highest recorded levels.* Traditional methods of disease surveillance do not capture all COVID-19 cases because some are asymptomatic, not diagnosed, or not reported; therefore, the proportion of the population with SARS-CoV-2 antibodies (i.e., seroprevalence) can improve understanding of population-level incidence of COVID-19. This report uses data from CDC's national commercial laboratory seroprevalence study and the 2018 American Community Survey to examine U.S. trends in infection-induced SARS-CoV-2 seroprevalence during September 2021-February 2022, by age group.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
Type of study:
Observational study
Topics:
Variants
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
MMWR Morb Mortal Wkly Rep
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS